Progress in the development of therapeutic antibodies targeting prion proteins and β-amyloid peptides

被引:3
|
作者
He JinSheng [1 ]
Zhang Ying [1 ]
Hong Tao [1 ,2 ]
机构
[1] Beijing Jiaotong Univ, Sch Sci, Coll Life Sci & Bioengn, Beijing 100044, Peoples R China
[2] Chinese Ctr Dis Control & Prevent, Inst Viral Dis Control & Prevent, Beijing 100052, Peoples R China
基金
国家高技术研究发展计划(863计划);
关键词
prion; Alzheimer's disease; immunotherapy; antibody; conformation; ANTI-PRP ANTIBODIES; MONOCLONAL-ANTIBODIES; A-BETA; ANTIIDIOTYPIC ANTIBODIES; ALZHEIMERS-DISEASE; CELL-LINES; EPITOPE; CONFORMATION; OLIGOMERS; FRAGMENT;
D O I
10.1007/s11427-010-4043-z
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Prion diseases and Alzheimer's disease (AD) are characterized by protein misfolding, and can lead to dementia. However, prion diseases are infectious and transmissible, while AD is not. The similarities and differences between these diseases have led researchers to perform comparative studies. In the last 2 decades, progress has been made in immunotherapy using anti-prion protein and anti-beta-amyloid antibodies. In this study, we review new ideas and strategies for therapeutic antibodies targeting prion diseases and AD through conformation dependence.
引用
收藏
页码:959 / 963
页数:5
相关论文
共 50 条
  • [1] Progress in the development of therapeutic antibodies targeting prion proteins and β-amyloid peptides
    HE JinSheng1
    2Institute for Viral Disease Control and Prevention
    Science China(Life Sciences), 2010, (08) : 959 - 963
  • [2] Progress in the development of therapeutic antibodies targeting prion proteins and β-amyloid peptides
    JinSheng He
    Ying Zhang
    Tao Hong
    Science China Life Sciences, 2010, 53 : 959 - 963
  • [3] Progress in the development of therapeutic antibodies targeting prion proteins and β-amyloid peptides
    HE JinSheng ZHANG Ying HONG Tao College of Life Sciences and Bioengineering School of Science Beijing Jiaotong University Beijing ChinaInstitute for Viral Disease Control and Prevention Chinese Center for Disease Control and Prevention Beijing China
    Science China(Life Sciences), 2010, 53 (08) : 959 - 963
  • [4] Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins
    Zhou, Qun
    CURRENT DRUG TARGETS, 2018, 19 (13) : 1491 - 1497
  • [5] Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)
    Li, Chunxiao
    Li, Ting
    Tian, Xinya
    An, Wei
    Wang, Zhenlong
    Han, Bing
    Tao, Hui
    Wang, Jinquan
    Wang, Xiumin
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [6] Targeting Soluble Amyloid Oligomers in Alzheimer's Disease through Disordered Prion Peptides
    Levine, Zachary A.
    BIOPHYSICAL JOURNAL, 2019, 116 (03) : 495A - 495A
  • [7] Targeting prion amyloid deposits in vivo
    Sadowski, M
    Pankiewicz, J
    Scholtzova, H
    Tsai, J
    Li, YS
    Carp, RI
    Meeker, HC
    Gambetti, P
    Debnath, M
    Mathis, CA
    Shao, L
    Gan, WB
    Klunk, WE
    Wisniewski, T
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2004, 63 (07): : 775 - 784
  • [8] Neurotoxicity of beta-amyloid and prion peptides
    Forloni, G
    CURRENT OPINION IN NEUROLOGY, 1996, 9 (06) : 492 - 500
  • [9] Quinacrine reactivity with prion proteins and prion-derived peptides
    Zbigniew Zawada
    Martin Šafařík
    Eva Dvořáková
    Olga Janoušková
    Anna Březinová
    Ivan Stibor
    Karel Holada
    Petr Bouř
    Jan Hlaváček
    Jaroslav Šebestík
    Amino Acids, 2013, 44 : 1279 - 1292
  • [10] Quinacrine reactivity with prion proteins and prion-derived peptides
    Zawada, Zbigniew
    Safarik, Martin
    Dvorakova, Eva
    Janouskova, Olga
    Brezinova, Anna
    Stibor, Ivan
    Holada, Karel
    Bour, Petr
    Hlavacek, Jan
    Sebestik, Jaroslav
    AMINO ACIDS, 2013, 44 (05) : 1279 - 1292